Neo-adjuvant Immunotherapy in Patients With Localized Melanoma

The success of anti-PD-1 and anti-CTLA-4 therapies has initiated a paradigm shift in oncology, with drugs now targeting the immune system rather than cancer cells to stimulate the antitumor immune response. Intratumoral (IT) delivery of immunostimulating agents reduces the systemic toxicity associated with monoclonal antibodies (mAbs) targeting immune checkpoints. Notably, IT injections of immune checkpoint blockade (ICB) have been shown to induce immune-mediated tumor responses both at the injected site and at distant, non-injected tumor sites. While surgery has traditionally been the preferr

Trial Details

NCT ID
NCT07230613
Phase
PHASE2
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
Mucosal Melanoma Melanoma
Locations (sample)
  • Villejuif, France|48.7939,2.35992

Key Eligibility Criteria

  • Inclusion Criteria:
  • Patients ≥ 18 years old.
  • Patients with resectable and measurable (according to RECIST v1.1 criteria) stage III cutaneous and mucosal melanoma.
  • Patients who received anti-PD-1 and stopped treatment \> 6 months prior to their inclusion in NEO-1 trial are eligible.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Mucosal Melanoma Melanoma Trials on Trialify →